Loading...

GUTS FRACTYL HEALTH INC US FDA Inspections 8-K Filing

FRCT

GTS

FRACTYL HEALTH INC

(GUTS)

2025 8-K

Summary

Summary

Stockholder Meeting

Stock Offering Announcement

Interim Study Results

Equity Offerings

Product Expansion

Post-Market Surveillance

Clinical Trials

Product Expansion

Financial Statements

Positive Study Data

Annual Meeting Notice

Financial Results

Clinical Study Update

New Therapy Candidate

External Links:

On April 1, 2025, Fractyl Health, Inc. announced positive early data from its REMAIN-1 pivotal study, showing weight maintenance after GLP-1 discontinuation, with over 50% enrollment expected to complete by summer 2025.

AI Assistant

FRACTYL HEALTH INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.